169 related articles for article (PubMed ID: 8315572)
1. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
3. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
[TBL] [Abstract][Full Text] [Related]
4. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
5. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC
Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
7. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
[TBL] [Abstract][Full Text] [Related]
8. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
9. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
10. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
[TBL] [Abstract][Full Text] [Related]
11. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
12. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
[TBL] [Abstract][Full Text] [Related]
13. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
14. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.
McElrath MJ; Corey L; Berger D; Hoffman MC; Klucking S; Dragavon J; Peterson E; Greenberg PD
J Infect Dis; 1994 Jan; 169(1):41-7. PubMed ID: 8277196
[TBL] [Abstract][Full Text] [Related]
15. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
[TBL] [Abstract][Full Text] [Related]
16. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
17. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
Höglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B
Viral Immunol; 1990; 3(3):195-206. PubMed ID: 2257052
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
19. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA
Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585
[TBL] [Abstract][Full Text] [Related]
20. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
